INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

2006600 citationsJournal Article

Authors

Richard F. Spaide · Manhattan Eye, Ear and Throat Hospital

Ketan Laud

Abstract

There were no apparent short-term safety concerns for intravitreal bevacizumab injection for CNV. Treated eyes had a significant decrease in macular thickness and improvement in visual acuity. The follow-up was too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 26, Issue 4, pp. 383-390

DOI: 10.1097/01.iae.0000238561.99283.0e

Field-Weighted Citation Impact: 78.30

Command Palette